Tirzepatide is a first-in-class dual agonist that activates both GIP and GLP-1 receptors. By targeting both incretin systems, it produces greater weight loss and A1C reduction than selective GLP-1 agonists in head-to-head trials. FDA-approved for type 2 diabetes (Mounjaro 2022) and chronic weight management (Zepbound 2023). Half-life is about five days, supporting once-weekly subcutaneous dosing.
Drugs in this category
Related terms
- GIP
- Second gut hormone targeted by tirzepatide (Zepbound, Mounjaro). Dual GIP/GLP-1 action drives stronger weight loss than single-agonist drugs.
- GLP-1
- Glucagon-like peptide-1 receptor agonist — class of drugs that mimic a gut hormone to reduce appetite and slow stomach emptying.
- Semaglutide
- GLP-1 receptor agonist; active ingredient in Wegovy, Ozempic, and Rybelsus.
- SURPASS-2
- Head-to-head trial of Mounjaro (tirzepatide) vs Ozempic (semaglutide) in T2D.
- SURMOUNT-1
- Pivotal 72-week trial behind Zepbound's FDA approval. Average 20.9% body weight loss at the 15 mg dose.